Simmons & Simmons has advised Ascendis Pharma A/S on the German law aspects of its US$108 million Initial Public Offering on NASDAQ.

Ascendis Pharma is a biopharmaceutical company focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs.

The Simmons & Simmons team was led by Düsseldorf based corporate and M&A partner Stephan Ulrich who has already acted for Ascendis in recent years. The team also included tax partner Bernulph von Crailsheim, corporate and M&A counsel Christian Bornhorst, antitrust supervising associate Martin Gramsch, corporate and M&A associates Matthias von Holten and Patrick Rivet, employment associate Laura Klare, and tax associate Elmar Weinand.